Phaseline

Targets › MMUT

MMUT (Methylmalonyl-CoA mutase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Apr 2034.

Catalyzes the reversible isomerization of methylmalonyl-CoA (MMCoA) (generated from branched-chain amino acid metabolism and degradation of dietary odd chain fatty acids and cholesterol) to succinyl-CoA (3-carboxypropionyl-CoA), a key intermediate of the tricarboxylic acid cycle. (UniProt, P22033)

Open in Phaseline: the race on MMUT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ModernaTXmRNA-3705
modified mRNA encoding human methylmalonyl-coenzyme A mutase (MUT)
MMUTPhase 1Methylmalonic AcidemiaApr 2034

Conditions

Methylmalonic Acidemia (1)

Modalities

other (1)

Companies

ModernaTX (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.